Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alfacell Plans Subset Onconase NDA Despite Phase III Shortfall In Mesothelioma

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug works in chemo failures; filing by year’s end, CFO tells “The Pink Sheet” DAILY.

You may also be interested in...



Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos

Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.

Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos

Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.

Alfacell Finishes Six-Year Mesothelioma Study

Firm opens Phase IIIb database on would-be competitor to Lilly’s Alimta.

Topics

UsernamePublicRestriction

Register

PS067819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel